SCHEMBL30980513

SCHEMBL30980513

C#C[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.51
▸ THRB P10828 1/20 0.51
▸ MAPK1 P28482 2/20 0.49
▸ CD69 Q07108 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ PYGB P11216 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ OGA O60502 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980761 1.00 ALDH1A1 (0.51) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL25345825 0.81 ALDH1A1 (0.50) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL25345827 0.81 ALDH1A1 (0.50) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL12936319 0.80 ALDH1A1 (0.58) ALDH1A1THRBMAPK1CD69SMN1; SMN2
SCHEMBL17771655 0.80 ALDH1A1 (0.58) ALDH1A1THRBMAPK1CD69SMN1; SMN2
N-Acetylglucosamine SCHEMBL24276732 0.79 MAPK1 (0.63) ALDH1A1THRBMAPK1CD69SMN1; SMN2
N-Acetylglucosamine SCHEMBL20621758 0.79 MAPK1 (0.63) ALDH1A1THRBMAPK1CD69SMN1; SMN2
N-Acetylglucosamine SCHEMBL25229254 0.79 MAPK1 (0.63) ALDH1A1THRBMAPK1CD69SMN1; SMN2
N-Acetylglucosamine SCHEMBL22748805 0.79 MAPK1 (0.63) ALDH1A1THRBMAPK1CD69SMN1; SMN2
N-Acetylglucosamine SCHEMBL20842453 0.79 MAPK1 (0.63) ALDH1A1THRBMAPK1CD69SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 — — WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
Send feedback